By selecting the Yes option, leaving Amgen.ie option you understand that you are leaving the corporate page of Amgen Ireland and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen is one of the world's leading biotechnology companies, present in more than 100 countries and regions worldwide, with a global team of 23,000 employees.
We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on four therapeutic areas: oncology, inflammation, general medicine and rare disease, delivering innovative medicines to help people live longer, fuller, happier lives.
We pursue new ways to do science using tools like AI, generative biology and human data to discover what is not yet known and develop new precision medicines to fight the world’s toughest diseases.
Many of Amgen's medicines are made through a highly complex process involving living cells. Our commitment is to deliver for "every patient, every time", and we have a long-running reputation for the reliability of our supply chain.
Making a positive difference in the world is at the heart of what we do at Amgen — and it goes beyond making vital medicines. We also help build a better world by focusing on environmental, social and governance issues that matter most to our business and our stakeholders.
Amgen has had a presence in Ireland for over 25 years. We established our Irish commercial operation in 1998 and we now employ 1,250 people across our three sites.
Our commercial team is based in Santry, North Dublin, and comprises sales, marketing, medical and market access functions.
With a focus on a diverse portfolio that includes general medicine, oncology, biosimilars and rare disease medicines, our colleagues are committed to providing access to patients.
Working in partnership with the health service, healthcare professionals and patient groups, they are passionate about shaping a favourable medicines access environment in Ireland.
In 2011, we acquired a manufacturing facility in Dún Laoghaire, Co Dublin and undertook a significant expansion programme at the site with a total investment of $1 billion.
The 32-acre facility specialises in formulation, aseptic drug product filling, lyophilisation, packaging as well as analytical testing using on-site laboratories. The site also has cold chain and ambient warehouses. The facility can lyophilize 100,000 vials at a time and fill 25,000 syringes per hour.
We export the products manufactured at our Dún Laoghaire facility to over 50 countries. The site is Amgen’s largest manufacturing facility outside the US.
Our Waterford facility is our newest manufacturing plant in Ireland, which we acquired in 2023 following our acquisition of Horizon Therapeutics.
The facility is focused on drug product development and clinical and commercial manufacturing for Amgen’s rare disease business unit. The Waterford site is a flexible, multi-format, single-use facility supported by quality control and process development capabilities.